 |
 |
|
Welcome to Drug Delivery E-News. Over the next few weeks subscribers will be receiving their own personal copy of the newly titled Drug Delivery Report Autumn Winter 2005 - our most successful (and substantial) edition to-date. So watch out for your copy arriving in the post.
PharmaVentures Intelligence End of Year Report ReductionsOrder your specially priced copy of either the 'Effective Licensing & Commercialisation of Drug Delivery Systems' and/or 'Facts and Trends in Deal Making'. Stocks are limited, so make sure you receive your copy and order today.50% reduction in the Effective Licensing & Commercialisation of Drug Delivery Systems Report View contentsTo Order 30% reduction in the Facts and Trends in Deal Making - A Perspective on the Pharma and Biotech Industry View contentsTo Order |
||
 |
 |
 |
Market News and TrendsDuring October PharmaDeals® Agreements has recorded 26 deals relating to drug delivery. A review of these deals shows that one of the largest headline values among these announcements was from the agreement between Syntonix and Boehringer Ingelheim, where the potential value of the deal is up to US$63 M (Deal no. 22096). The collaboration the companies entered into is to optimise certain Boehringer Ingelheim therapeutic peptides for inhalation using Syntonix's SynFusion™ and Transceptor™ technologies. Read more... |
||
|
|
||
Featured ArticleNew-Generation Auto-Injectors: Completing the Scale of Convenience for Self-injectionThe market for pens and auto-injectors continues to grow for the convenient self-injection of biopharmaceuticals. Pre-filled syringes are becoming increasingly widespread for self-injection and auto-injectors are helping to simplify their use in new and existing therapeutic areas. In this article, Ian Thompson of Ypsomed AG discusses the history of self-injection devices over the last twenty years and the development of new and sophisticated devices, including Ypsomed's Auto-Injector, which works with the UltraSafe® Delivery System. Ian Thompson shows how such devices can be created in a variety of customised designs in order to meet the needs of a wide range of patient groups, safely and reliably. Read more... |
 |
||
|
|
||
 |
Company ProfilesAphios, Cancer Research Technology, Lyfjathroun, Phares |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity Liposomal Topotecan Administrative route - Intravenous Indication - Cancer Licence code LO-1005-04 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Companies Spring / Summer 2006For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Paul Sanders, Product Manager, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz